IMUXbenzinga

Immunic Announced Presentation Of Data On Nuclear Receptor-Related 1 (Nurr1) Activator, Vidofludimus Aalcium (IMU-838), In Two Poster Presentations At The Americas Committee For Treatment And Research In Multiple Sclerosis Forum 2025

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on February 26, 2025 by benzinga